Compositions comprising sulfated polysaccharides

Abstract

The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.

1 . A composition comprising at least one anti-inflammatory agent, and at least one sulfated polysaccharide. 
     
     
         2 . The composition according to  claim 1 , wherein the anti-inflammatory agent(s) and the sulfated polysaccharide(s) are present in relative amounts such that there is a synergistic interaction between said anti-inflammatory agents and said sulfated polysaccharide(s). 
     
     
         3 . The composition according to  claim 1 , wherein the weight ratio of the one or more anti-inflammatory agents to the one or more sulfated polysaccharides is in the range of 1:0.0001-1:100. 
     
     
         4 . The composition according to  claim 1 , wherein the weight ratio of the one or more anti-inflammatory agents to the one or more sulfated polysaccharides is in the range of 1:0.01-1:10. 
     
     
         5 . The composition of  claim 1 , wherein the anti-inflammatory agent is selected from the group consisting of: steroid drugs, non-steroidal anti-inflammatory drugs, cannabinoids and combinations thereof. 
     
     
         6 . The composition of  claim 5 , wherein the anti-inflammatory agent is a steroid drug. 
     
     
         7 . The composition of  claim 6 , whereas the anti-inflammatory steroid drug is selected from the group consisting of dexamethasone, prednisolone, mometasone, halomethasone, betamethasone, betamethasone valerate or succinate, fluorocinolone, triamcinolone, clobetasole, diflorazone, Loteprednol etabonate and hydrocortisone and mixtures thereof. 
     
     
         8 . The composition of  claim 5 , wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug. 
     
     
         9 . The composition of  claim 8 , wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of acetaminophen, ibuprofen, diclofenac, aspirin, indomethacin, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, ketoprofen, piroxicam, tramadol, celecoxib and flurbiprofen, or a salt thereof and mixtures thereof. 
     
     
         10 . The composition of  claim 5 , wherein the anti-inflammatory agent is a cannabinoid. 
     
     
         11 . The composition of  claim 1 , wherein the sulfated polysaccharide is selected from the group consisting of algal sulfated polysaccharides, sulfated polysaccharides of herbal origin, bacterial sulfated polysaccharides and combinations thereof. 
     
     
         12 . The composition of  claim 1 , wherein the sulfated polysaccharide is of marine origin selected from the group consisting of unicellular and multicellular algae. 
     
     
         13 . The composition of  claim 1 , wherein the sulfated polysaccharides are of extracellular origin. 
     
     
         14 . The composition of  claim 1 , wherein the sulfated polysaccharides are branched polysaccharides. 
     
     
         15 . The composition of  claim 1 , wherein the sulfated polysaccharides are linear polysaccharides. 
     
     
         16 . The composition of  claim 1 , further comprising one or more excipients selected from the group consisting of fillers, solvents, stabilizers, suspending agents, emulsifiers, release mediators, viscosity agents, anti-microbial agents and preservatives, and combinations thereof. 
     
     
         17 . The composition of  claim 1 , wherein said composition is formulated as a dosage form selected from the group consisting of a liquid, a suspension, an emulsion, a foam, a spray, a liposome, a semi-solid, a cream, an ointment, a patch, a particulate formulation, a granulate, a micro-particulate formulation, a nano-particulate formulation, a solid dosage form, a tablet, a capsule, an orally-disintegrable capsule, a mouth wash and an adhesive buccal tablet. 
     
     
         18 . The composition of  claim 1 , wherein the release profile of the composition is selected from the group consisting of immediate, delayed, controlled, sustained and prolonged. 
     
     
         19 . A method for treating inflammation comprising administering to a human or mammalian subject a composition according to  claim 1 . 
     
     
         20 . The method of  claim 19 , wherein the inflammation is associated with one or more conditions selected from the group consisting of infection due to bacteria, viruses or fungi, allergens, cancer, and physical, chemical, autoimmune disease or thermal trauma. 
     
     
         21 . The method of  claim 19 , wherein the inflammation is associated with a disease selected from one or more of a disease, disorder or condition selected from the group consisting of eye diseases, dry eyes, kerato conjunctivitis, wounds, ulcerative and diabetic wounds, oral mucositis, chemotherapy, radiation-induced inflammation, inflammatory bowel diseases, liver diseases, skin infections, skin allergies, psoriasis, mucosal inflammation and gastro-intestinal infections and inflammations, ear diseases or infections, throat or gum inflammations, vaginal inflammation and anal inflammation.